SynthesisFrontiers in public health2026
Global seroepidemiology of pertussis: a systematic review and meta-analysis.
Synthesis in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pertussis remains a global health concern despite widespread vaccination. Clinical reporting underestimates true disease burden due to underdiagnosis and asymptomatic cases. Consequently, serological surveillance is essential for accurately assessing infection rates and population immunity. Methods: We conducted a systematic review and meta-analysis of studies published between January 2014 and October 2024 in PubMed, Web of Science, EMBASE, and the Cochrane Library. Observational studies reporting the seropositivity rate of PT-IgG or recent pertussis infection rate in general populations were included. Pooled estimates were calculated using random-effects models, with subgroup analyses by region, sex, age, and investigation year. Results: Analyzing 64 studies involving approximately 87,000 participants from 37 countries, the global pooled seropositivity rate was 23.3% (95% CI: 17.2-30.1%), and the recent infection rate was 3.6% (95% CI: 2.4-5.0%). Seropositivity exhibited a trimodal distribution: the first peak in infants aged 1-2 (25.8%), the highest peak in adolescents aged 10-19 (26.2%), a nadir in adults aged 20-39 (17.1%), followed by a tertiary rise in individuals ≥40 years (20.5%). Recent infection rates showed a similar pattern. Regional disparities were significant, with the Americas showing the highest seropositivity (51.2%), while the Eastern Mediterranean Region reported the highest recent infection rate (10.3%). Temporally, seropositivity increased from 18.0% (2011-2015) to 25.9% (2016-2022), whereas recent infection rates declined from 6.4 to 2.7%. Conclusion: This study confirms the ongoing global circulation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.